18 results about "Octreotide" patented technology

Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.

The invention provides a salt type crystal of octreotide as well as a preparation method and application of the salt type crystal. The crystal has characteristic peaks when the 2 theta value is 7.7 degrees + / -0.2 degrees, 8.7 degrees + / -0.2 degrees, 9.5 degrees + / -0.2 degrees, 10.2 degrees + / -0.2 degrees, 13.6 degrees + / -0.2 degrees and 18.3 degrees + / -0.2 degrees by using X-ray powder diffraction of Cu-K alpha radiation. The orotate crystal form I of octreotide provided by the invention has the advantages in at least one aspect of solubility, melting point, stability, dissolution rate, hygroscopicity, adhesiveness, fluidity, bioavailability, processability, purification effect, preparation production, safety and the like, and provides a new better choice for preparation of a pharmaceutical preparation containing octreotide; and the method has very important significance on drug development.

The present invention provides a combination of two or more imaging agent conjugates comprising an imaging agent conjugated to a targeting ligand, wherein the imaging agent comprises one or more of: ZW800-1, ZW830-1, ZW700-1-Forte, ZW-DOTA, ZW-PyC3A, ZW-Macropa, ZW-Porphyrin, ZW-NOTA, and ZW-Deferoxamine; and the targeting ligand comprises one or more of: cRGD, dPSMA-617 or KUE, FAP, Bombesin Receptor Binding Vector, or Octreotide Binding Vector, or one or more of the peptides selected from SEQ ID Nos: 1 to 4.

The utility model discloses filling equipment for octreotide microsphere injection, and belongs to the technical field of medicine bottle filling equipment. A visual camera is arranged, the visual camera is used for observing the liquid level in a medicine bottle on a material sliding plate and monitoring the height of the liquid level, a drawing plate is arranged on the material sliding plate in a matched mode, when a defective medicine bottle appears, a driving air cylinder is used for driving the drawing plate to slide, and the defective medicine bottle can be separated from the material sliding plate and slide out of the material sliding plate; and a visual camera is beneficial to improving the consistency of judgment, and the cooperation of a drawing plate and a driving air cylinder is beneficial to quickly removing defective medicines, so that the filling quality of the medicine bottles is greatly improved.

The present invention provides a combination of two or more imaging agent conjugates comprising an imaging agent conjugated to a targeting ligand, wherein the imaging agent comprises one or more of ZW800-1, ZW830-1, ZW700-1-Forte, ZW-DOTA, ZW-PyC3A, ZW-Macropa, ZW-porphyrin, ZW-NOTA, and ZW-Deferoxamine; and the targeting ligand comprises one or more of a cRGD, a dPSMA-617 or a KUE, a FAP, a bombesin receptor binding vector, or a octreotide binding vector, or one or more of peptides selected from SEQ ID No: 1-4.

Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.

The invention discloses a pharmaceutical composition for preventing and / or treating acute pancreatitis. The Anarinone root plays a role in preventing and treating acute pancreatitis by inhibiting oxidative stress (such as improving the activity of superoxide dismutase (SOD) and reducing the content of malondialdehyde (MDA)) and / or inhibiting inflammatory response (such as inhibiting activation of an NF-kappa B signal channel and reducing expression of proinflammatory factors such as IL-6, TNF-alpha and the like); compared with a chemical synthetic medicine octreotide (possibly causing gastrointestinal reaction, abnormal blood glucose and other side effects), the long-term use experience of the Anacarid root serving as a traditional habitual natural medicinal material shows that the Anacarid root possibly has better biocompatibility and lower adverse reaction risk, and a possibly safer treatment choice is provided for patients.

This disclosure provides compositions and methods for treating neuroendocrine tumors. A lipid composition comprising 20 mg of octreotide is administered to a patient once every two weeks. The lipid composition provides slow release of octreotide.

Provided herein are methods for treating one or more symptoms associated with neuroendocrine tumors, such as episodes of diarrhea and flushing associated with carcinoid tumors, and methods for treating carcinoid syndrome, comprising orally administering a composition comprising octreotide or a pharma- ceutically acceptable salt thereof.

The present invention relates to a mixed green solvent based process for the preparation of peptide. More specifically, the present invention relates to a process of the preparation of Octreotide using greener solvent. The process of present invention also focused on minimizing solvent consumption, especially DMF, trifluoroacetic acid (TFA) and ethers. The process of present invention also substitutes acetonitrile with methanol in the chromatographic purification steps. The process of present invention only addresses environmental concerns associated with DMF usage but also maintains the efficiency and effectiveness of the Octreotide synthesis process.

The invention provides an octreotide-D-configuration oncolytic peptide conjugate as well as a preparation method and application thereof, and belongs to the technical field of polypeptide preparation and biological medicine. The invention designs and synthesizes a pH-responsive octreotide-D-configuration oncolytic peptide conjugate aiming at the defects that an L-configuration oncolytic peptide is poor in stability, low in anti-tumor activity, high in toxicity to normal cells, only capable of performing intratumor injection and the like. The pH-responsive octreotide-D-configuration oncolytic peptide conjugate can significantly improve the anti-tumor activity and stability of the oncolytic peptide, and shows a stronger tumor cell proliferation inhibition effect. The conjugate provided by the invention has the advantages of lower toxicity to normal cells, higher activity to high-expression somatostatin receptor tumor cell lines and the like, and meanwhile, the administration mode of the oncolytic peptide can be optimized, so that the conjugate has a good practical application value.

A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGP-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.

The invention provides a preparation method of several < 68 > Ga labeled somatostatin receptor (SSTR) probes, and belongs to the technical field of nuclear medicine radiopharmaceuticals. The SSTR targeting compound octreotide is structurally modified by changing types and configurations of amino acids, changing disulfide bonds and increasing non-traditional amino acids on the basis of the existing SSTR targeting compound octreotide, and the series of probes have the advantages of good stability, high targeting property, higher tumor / normal tissue ratio (target / non-target ratio) and the like. The invention not only has a good application prospect in the aspect of PET / SPECT (positron emission tomography / single photon emission computed tomography) imaging agents of high-expression SSTR diseases, but also has potential advantages in the aspect of radioactive therapy of SSTR high-expression tumors.

The present invention relates to a preparation method and application of a polymer nano drug targeting somatostatin receptor 2, effectively solving the problem of preparing a polymer nano drug targeting somatostatin receptor 2, and its application in preparing a drug for treating neuroendocrine prostate cancer, wherein PLGA-PEG-Mal is dissolved in dichloromethane, double distilled water is added, and the suspension is initially emulsified, and then a sodium cholate aqueous solution is added for double emulsion, and the suspension after the two emulsifications is added dropwise to the sodium cholate aqueous solution, and the suspension is dispersed by magnetic stirring, and the dichloromethane in the solution is removed by rotary evaporation under reduced pressure, centrifuged, and the precipitate is washed twice with double distilled water, and then the precipitate is resuspended in double distilled water to obtain a PLGA nanoparticle suspension; octreotide is mixed with the PLGA nanoparticle suspension, double distilled water or PBS buffer is added, and the suspension is placed in a suspension instrument for reaction, dialyzed, and unconnected octreotide is removed to obtain a polymer nano drug targeting somatostatin receptor 2. The method of the present invention is easy to operate, has a scientific and reasonable design, and has good performance of the prepared product.

Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.

Provided herein are methods of treating one or more symptoms associated with neuroendocrine tumors, such as diarrhea and flushing episodes associated with carcinoid tumors and methods of treating carcinoid syndrome, comprising orally administering compositions comprising octreotide or a pharmaceutically acceptable salt thereof.

The present invention provides a mixed release profile polymeric microsphere formulation comprising octreotide. In one aspect, the microsphere formulation is characterized by an in vivo release time of octreotide in a human body of about 60 days. The invention also provides methods of making and using these formulations.

This invention provides an octreotide-D-configuration oncolytic peptide conjugate, its preparation method, and its applications, belonging to the fields of peptide preparation and biomedical technology. Addressing the shortcomings of L-configuration oncolytic peptides, such as poor stability, low antitumor activity, high cytotoxicity to normal cells, and limitation to intratumoral injection, this invention designs and synthesizes a pH-responsive octreotide-D-configuration oncolytic peptide conjugate. This pH-responsive octreotide-D-configuration oncolytic peptide conjugate significantly improves the antitumor activity and stability of the oncolytic peptide, exhibiting a stronger inhibitory effect on tumor cell proliferation. The conjugate provided by this invention has advantages such as lower toxicity to normal cells and stronger activity against tumor cell lines highly expressing somatostatin receptors. Furthermore, this invention can optimize the administration method of the oncolytic peptide, thus possessing good practical application value.